Stock ROIV ROIVANT SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
10.94 USD -3.10% Intraday chart for Roivant Sciences Ltd. -4.12% -2.58%
May. 20 Transcript : Roivant Sciences Ltd. Presents at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, May-20-2024 09:00 AM
Apr. 05 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
GL
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024
AQ
Roivant Sciences : NIU Phase 2 Topline Results
PU
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
GL
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
GL
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
AQ
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
GL
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
AQ
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
AQ
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
GL
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
GL
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
AQ
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
GL
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
AQ
Cerence, Roivant Sciences fall; Xenon Pharmaceuticals, Shopify rise, Monday, 11/27/2023
AQ
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
GL
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
AQ
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
GL
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
AQ
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROIV Stock
  4. News Roivant Sciences Ltd.
  5. Press Releases